Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

CD34+ Selected Stem Cell for Poor Graft Function or Graft Failure

NCT: NCT06569082 · RECRUITING

NCT IDNCT06569082

StatusRECRUITING

Start Date2024-10-31

SponsorNYU Langone Health (OTHER)

First posted2024-08-23

Last updated2026-08-17

Brief Summary

The proposed trial is a single arm, non-randomized, single center pilot study utilizing CliniMACS CD34 Reagent System for patients following allogeneic hematopoietic stem cell transplant (HSCT) requiring treatment of graft dysfunction or failure.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑